Get the content you want anytime you want.
REGISTER NOW | SIGN IN

The Contagion® MRSA specialty page provides MRSA-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

MRSA VIDEOS - Page 1

What Makes Eravacycline a Unique Antibiotic?
Patrick Horn, MD, PhD, explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.
Who is Not a Good Candidate for MRSA Prodrug TXA709?
Daniel Pilch, PhD, explains which patients would not make good candidates for MRSA prodrug TXA709.
Developing New Antibiotics: What's the Best Approach to Take?
Daniel Pilch, PhD, discusses the approach that he and his team took to develop a new drug to fight MRSA.
What Are the Special Properties of MRSA Prodrug TXA709?
Edmond LaVoie, PhD, describes the properties of prodrug TXA709.
Rutgers Researchers Develop New MRSA Prodrug: Can the Pathogen Gain Resistance?
Daniel Pilch, PhD, discusses the potential of Staphylococcus aureus to develop resistance to TXA709.
What is the Role of Combination Therapy in Treating <i>S. aureus</i> Infections?
Prof. Josh Davis, MBBS, PhD, discusses the role of combination therapy when it comes to treating invasive Staphylococcus aureus infections.
Examining the Bactericidal Behavior of a New MRSA Treatment
Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains the bactericidal behavior of TXA709, a new drug to treat MRSA infections.
How Does TXA709 Target MRSA?
Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, co-founder of TAXIS Pharmaceuticals, and co-author of the study on the new MRSA drug, TXA709, explains how TXA709 targets MRSA differently than other antibiotics.